Published in J Thorac Oncol on February 01, 2008
Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. J Clin Oncol (2014) 4.31
Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol (2005) 2.76
Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol (2008) 2.20
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol (2009) 1.88
Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol (2008) 1.84
Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J Natl Cancer Inst (2010) 1.83
A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol (2011) 1.74
Shifting patterns in the interpretation of phase III clinical trial outcomes in advanced non-small-cell lung cancer: the bar is dropping. J Clin Oncol (2014) 1.61
Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. J Clin Oncol (2009) 1.25
A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. Oncologist (2010) 1.22
Clinical outcomes of extensive stage small cell lung carcinoma patients treated with consolidative thoracic radiotherapy. Clin Lung Cancer (2011) 1.09
Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. J Thorac Oncol (2007) 1.07
KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol (2013) 1.05
Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer. Chest (2005) 1.01
Barriers and challenges to global clinical cancer research. Oncologist (2013) 1.01
Locoregional failures following thoracic irradiation in patients with limited-stage small cell lung carcinoma. Radiother Oncol (2012) 1.00
Development and evaluation of a decision aid for patients considering first-line chemotherapy for metastatic breast cancer. Health Expect (2008) 1.00
Challenges to implementation of an epidermal growth factor receptor testing strategy for non-small-cell lung cancer in a publicly funded health care system. J Thorac Oncol (2013) 1.00
Impact and feasibility of a comprehensive geriatric assessment in the oncology setting: a pilot study. Am J Clin Oncol (2012) 0.98
Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. J Clin Oncol (2009) 0.96
Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer. Lung Cancer (2011) 0.96
Sample features associated with success rates in population-based EGFR mutation testing. J Thorac Oncol (2014) 0.93
Ancillary testing in lung cancer diagnosis. Pulm Med (2012) 0.92
Differential role of estrogen receptor beta in early versus metastatic non-small cell lung cancer. Horm Cancer (2012) 0.90
Docetaxel in non-small cell lung cancer: impact on quality of life and pharmacoeconomics. Drugs Aging (2007) 0.87
Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses. Per Med (2009) 0.87
How affordable are targeted therapies in non-small cell lung cancer? Curr Treat Options Oncol (2011) 0.85
Second-hand smoke as a predictor of smoking cessation among lung cancer survivors. J Clin Oncol (2014) 0.85
Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC? J Thorac Oncol (2013) 0.84
Utilization of prophylactic cranial irradiation in patients with limited stage small cell lung carcinoma. Cancer (2010) 0.83
Derivation of utility values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire values in lung cancer. J Thorac Oncol (2010) 0.83
Do economic evaluations of targeted therapy provide support for decision makers? Am J Manag Care (2011) 0.81
Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Cancer (2009) 0.81
Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada. J Thorac Oncol (2014) 0.81
Initial treatment strategies and outcomes for multifocal bronchioloalveolar carcinoma. Clin Lung Cancer (2009) 0.80
End-of-life home care utilization and costs in patients with advanced colorectal cancer. J Community Support Oncol (2014) 0.80
Guidelines for health technologies: specific guidance for oncology products in Canada. Value Health (2012) 0.80
Long-term outcome after en bloc resection of non-small-cell lung cancer invading the pulmonary sulcus and spine. J Thorac Oncol (2013) 0.79
Do economic evaluations of targeted therapy provide support for decision makers? J Oncol Pract (2011) 0.78
Targeting the phosphatidylinosital 3-kinase, Akt, and mammalian target of rapamycin pathway in non-small cell lung cancer. J Thorac Oncol (2011) 0.77
Closing the personalized medicine information gap: HER2 test documentation practice. Am J Manag Care (2013) 0.77
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. J Thorac Oncol (2012) 0.77
Central Nervous System Pseudoprogression in a Patient Treated with PD-1 Checkpoint Inhibitor. J Thorac Oncol (2015) 0.77
Targeting vascular endothelial growth factor in lung cancer. J Thorac Oncol (2010) 0.76
Positron emission tomography use and stage migration in lung cancer: a false sense of accomplishment? J Clin Oncol (2012) 0.75
Gefitinib: a consideration of cost. Expert Rev Pharmacoecon Outcomes Res (2008) 0.75